Personal information

Emails & domains

Verified email domains

Countries

Japan

Activities

Collapse all

Employment (1)

The Cancer Institute Hospital: Tokyo, JP

2003-09-01 to present (Pharmacy)
Employment
Source: Self-asserted source
Takeshi Aoyama

Education and qualifications (1)

Showa University: Tokyo, JP

2017-04-01 to present | Ph.D
Education
Source: Self-asserted source
Takeshi Aoyama

Works (13)

Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology

ESMO Open
2024-10 | Journal article
DOI: 10.1016/j.esmoop.2024.103932
Contributors: K. Matsumoto; Y. Ryushima; J. Sato; Y. Aizawa; T. Aoyama; Y. Akaishi; R. Okamoto; Y. Sato; K. Sugano; K. Tazumi et al.
Source: check_circle
Crossref

Safety evaluation of fixed‐dose nivolumab in patients with gastric cancer

Health Science Reports
2022-07 | Journal article
DOI: 10.1002/hsr2.673
Contributors: Yusuke Iikura; Takeshi Aoyama; Makoto Hiraide; Takeru Wakatsuki; Izuma Nakayama; Mariko Ogura; Akira Ooki; Daisuke Takahari; Keisho Chin; Kensei Yamaguchi et al.
Source: check_circle
Crossref

Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers

Cancer Chemotherapy and Pharmacology
2021-06-26 | Journal article
DOI: 10.1007/s00280-021-04237-x
Contributors: Kazuo Kobayashi; Erika Sugiyama; Eiji Shinozaki; Takeru Wakatsuki; Masataka Tajima; Hiyori Kidokoro; Takeshi Aoyama; Yasuhiro Nakano; Kazuyoshi Kawakami; Koki Hashimoto et al.
Source: check_circle
Crossref

Comparison of cisplatin-induced nephrotoxicity when using conventional versus short hydration in gastric cancer—a retrospective study

Journal of Chemotherapy
2020-04-02 | Journal article
DOI: 10.1080/1120009X.2020.1713507
Contributors: Takeshi Aoyama; Takashi Tsunoda; Hiroki Kato; Akane Hagino; Ryota Furutani; Kazuyuki Ito; Hidenori Yoshioka; Masashi Nakamura; Makoto Hiraide; Kazuyoshi Kawakami et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy.

Anticancer research
2020-02 | Journal article
DOI: 10.21873/anticanres.14024
PMID: 32014935
Contributors: Yokokawa T; Suzuki K; Sugisaki T; Kobayashi K; Shouji D; Watanabe H; Kawakami K; Takiguchi T; Aoyama T; Kobayashi K et al.
Source: Self-asserted source
Takeshi Aoyama via Europe PubMed Central

Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma.

Oncology
2020-01 | Journal article
DOI: 10.1159/000505340
PMID: 31935736
Contributors: Kobayashi K; Suzuki K; Hiraide M; Aoyama T; Yokokawa T; Shikibu S; Hashimoto K; Iikura Y; Sato H; Sugiyama E et al.
Source: Self-asserted source
Takeshi Aoyama via Europe PubMed Central

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer.

Patient preference and adherence
2019-10 | Journal article
DOI: 10.2147/PPA.S217835
PMID: 31686792
PMC: PMC6800560
Contributors: Kawakami K; Wakatsuki T; Soejima A; Kobayashi K; Yokokawa T; Aoyama T; Suzuki K; Suenaga M; Yamaguchi K; Inoue A et al.
Source: Self-asserted source
Takeshi Aoyama via Europe PubMed Central

Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.

Oncology
2019-02 | Journal article
DOI: 10.1159/000495989
PMID: 30763946
Contributors: Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K et al.
Source: Self-asserted source
Takeshi Aoyama via Europe PubMed Central

[Safety Profile of the Combination of Prophylactic Pegfilgrastim and Cabazitaxel for Japanese Patients with Castration Resistant Prostate Cancer].

Gan to kagaku ryoho. Cancer & chemotherapy
2018-12 | Journal article
PMID: 30587731
Contributors: Azuma K; Kawakami K; Yuasa T; Sugisaki T; Hashimoto K; Aoyama T; Suzuki K; Yonese J; Hama T
Source: Self-asserted source
Takeshi Aoyama via Europe PubMed Central

Regorafenib-Induced Hand-Foot Skin Reaction is More Severe on the Feet than on the Hands.

Oncology research
2018-06 | Journal article
DOI: 10.3727/096504018x15291727589740
PMID: 29914591
Contributors: Nonomiya Y; Yokokawa T; Kawakami K; Kobayashi K; Aoyama T; Takiguchi T; Sugisaki T; Suzuki K; Suenaga M; Wakatsuki T et al.
Source: Self-asserted source
Takeshi Aoyama via Europe PubMed Central

Antiemetic Effects of Granisetron or Metoclopramide Administered Prior to Amrubicin Monotherapy

Oncomedicine
2017 | Journal article
Source: Self-asserted source
Takeshi Aoyama

Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study.

Oncology
2016-08 | Journal article
DOI: 10.1159/000448717
PMID: 27513940
Contributors: Sugita K; Kawakami K; Yokokawa T; Sugisaki T; Takiguchi T; Aoyama T; Suzuki K; Suenaga M; Yamaguchi K; Inoue A et al.
Source: Self-asserted source
Takeshi Aoyama via Europe PubMed Central

[Drug information brochure for patients undergoing FOLFOX 4 chemotherapy based on survey of adverse reactions].

Gan to kagaku ryoho. Cancer & chemotherapy
2007-09 | Journal article
PMID: 17876140
Contributors: Imada H; Kawakami K; Hiraoka T; Higuchi S; Takahashi G; Aoyama T; Shinozaki E; Suenaga M; Matsuzaka S; Hama T
Source: Self-asserted source
Takeshi Aoyama via Europe PubMed Central

Peer review (6 reviews for 1 publication/grant)

Review activity for Journal of pharmaceutical health care and sciences. (6)
How many people are using ORCID?